299 related articles for article (PubMed ID: 32870433)
1. Thrombin Inhibition by Argatroban: Potential Therapeutic Benefits in COVID-19.
Aliter KF; Al-Horani RA
Cardiovasc Drugs Ther; 2021 Apr; 35(2):195-203. PubMed ID: 32870433
[TBL] [Abstract][Full Text] [Related]
2. Caution in Using the Activated Partial Thromboplastin Time to Monitor Argatroban in COVID-19 and Vaccine-Induced Immune Thrombocytopenia and Thrombosis (VITT).
Guy S; Kitchen S; Makris M; M Maclean R; Saccullo G; Vanveen JJ
Clin Appl Thromb Hemost; 2021; 27():10760296211066945. PubMed ID: 34905962
[TBL] [Abstract][Full Text] [Related]
3. Thrombin inhibitor argatroban modulates bone marrow stromal cells behaviors and promotes osteogenesis through canonical Wnt signaling.
Song J; Jiang N; Gan X; Zhi W; Zhu Z
Life Sci; 2021 Mar; 269():119073. PubMed ID: 33460666
[TBL] [Abstract][Full Text] [Related]
4. Ecarin modified rotational thrombelastometry: a point-of-care applicable alternative to monitor the direct thrombin inhibitor argatroban.
Schaden E; Schober A; Hacker S; Kozek-Langenecker S
Wien Klin Wochenschr; 2013 Mar; 125(5-6):156-9. PubMed ID: 23440521
[TBL] [Abstract][Full Text] [Related]
5. Argatroban: a direct thrombin inhibitor with reliable and predictable anticoagulant actions.
Escolar G; Bozzo J; Maragall S
Drugs Today (Barc); 2006 Apr; 42(4):223-36. PubMed ID: 16703119
[TBL] [Abstract][Full Text] [Related]
6. The effects of argatroban on thrombin generation and hemostatic activation in vitro.
Tanaka KA; Szlam F; Katori N; Sato N; Vega JD; Levy JH
Anesth Analg; 2004 Nov; 99(5):1283-1289. PubMed ID: 15502018
[TBL] [Abstract][Full Text] [Related]
7. [Experimental and clinical results with the thrombin inhibitor Argatroban].
Breddin HK
Hamostaseologie; 2002 Aug; 22(3):55-9. PubMed ID: 12215762
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic administration of the direct thrombin inhibitor argatroban reduces hepatic inflammation in mice with established fatty liver disease.
Kassel KM; Sullivan BP; Cui W; Copple BL; Luyendyk JP
Am J Pathol; 2012 Oct; 181(4):1287-95. PubMed ID: 22841818
[TBL] [Abstract][Full Text] [Related]
9. Synergistic antithrombotic properties of G4120, a RGD-containing synthetic peptide, and argatroban, a synthetic thrombin inhibitor, in a hamster femoral vein platelet-rich thrombosis model.
Imura Y; Stassen JM; Vreys I; Lesaffre E; Gold HK; Collen D
Thromb Haemost; 1992 Sep; 68(3):336-40. PubMed ID: 1440501
[TBL] [Abstract][Full Text] [Related]
10. Argatroban in the management of heparin-induced thrombocytopenia.
Babuin L; Pengo V
Vasc Health Risk Manag; 2010 Sep; 6():813-9. PubMed ID: 20859550
[TBL] [Abstract][Full Text] [Related]
11. Argatroban therapy for heparin-induced thrombocytopenia in a patient with coronavirus disease 2019.
Ogawa Y; Nagata T; Akiyama T; Nishida K; Kumasawa J; Kohno M; Kohata H; Gohma I
J Thromb Thrombolysis; 2020 Nov; 50(4):1012-1014. PubMed ID: 32780355
[No Abstract] [Full Text] [Related]
12. Argatroban more effectively inhibits the thrombin activity in synovial fluid than naturally occurring thrombin inhibitors.
Asanuma K; Yoshikawa T; Yoshida K; Okamoto T; Asanuma Y; Hayashi T; Akita N; Oi T; Nishimura A; Hasegawa M; Sudo A
Cell Mol Biol (Noisy-le-grand); 2016 May; 62(6):27-32. PubMed ID: 27262798
[TBL] [Abstract][Full Text] [Related]
13. Anticoagulation with argatroban for elective percutaneous coronary intervention: population pharmacokinetics and pharmacokinetic-pharmacodynamic relationship of coagulation parameters.
Akimoto K; Klinkhardt U; Zeiher A; Niethammer M; Harder S
J Clin Pharmacol; 2011 Jun; 51(6):805-18. PubMed ID: 20663996
[TBL] [Abstract][Full Text] [Related]
14. Studies on the different modes of action of the anticoagulant protease inhibitors DX-9065a and Argatroban. I. Effects on thrombin generation.
Nagashima H
J Biol Chem; 2002 Dec; 277(52):50439-44. PubMed ID: 12496240
[TBL] [Abstract][Full Text] [Related]
15. Combined administration of aspirin and a specific thrombin inhibitor in man.
Clarke RJ; Mayo G; FitzGerald GA; Fitzgerald DJ
Circulation; 1991 May; 83(5):1510-8. PubMed ID: 2022012
[TBL] [Abstract][Full Text] [Related]
16. Limitation of the activated partial thromboplastin time as a monitoring method of the direct thrombin inhibitor argatroban.
Guy S; Kitchen S; Maclean R; Van Veen JJ
Int J Lab Hematol; 2015 Dec; 37(6):834-43. PubMed ID: 26305560
[TBL] [Abstract][Full Text] [Related]
17. Small-molecule direct antithrombins: argatroban.
Fareed J; Jeske WP
Best Pract Res Clin Haematol; 2004 Mar; 17(1):127-38. PubMed ID: 15171962
[TBL] [Abstract][Full Text] [Related]
18. Antithrombotic actions of the thrombin inhibitor, argatroban, in a canine model of coronary cyclic flow: comparison with heparin.
Duval N; Lunven C; O'Brien DP; Grosset A; O'Connor SE; Berry CN
Br J Pharmacol; 1996 Jun; 118(3):727-33. PubMed ID: 8762100
[TBL] [Abstract][Full Text] [Related]
19. A synopsis of the clinical uses of argatroban.
Moledina M; Chakir M; Gandhi PJ
J Thromb Thrombolysis; 2001 Oct; 12(2):141-9. PubMed ID: 11729365
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of factor Xa-induced platelet aggregation by a selective thrombin inhibitor, argatroban.
Kawai H; Yamamoto T; Hara H; Tamao Y
Thromb Res; 1994 May; 74(3):185-91. PubMed ID: 8042187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
